North Carolina Plastic Surgeon - Latisse Grow Your Lashes

LATISSE®
There’s been a growing interest in this product ever since it was introduced. And it’s no wonder. LATISSE® is the first and only FDA-approved prescription treatment for inadequate or not enough eyelashes, growing them longer, fuller and darker.

Discover the LATISSE® difference.
LATISSE® solution is an actual growth treatment. In fact, it’s the only FDA-approved treatment clinically proven to grow lashes. And it’s the only lash growth product of its kind available by prescription. So you’ll need to talk to your doctor to see if it’s right for you.

LATISSE® grows lashes longer, fuller and darker.
LATISSE® solution is a once-a-day treatment you apply topically to the base of your upper eyelashes, as instructed by your doctor. Then, gradually, the results come in. You may start to see more length in as little as 4 weeks and you should achieve full growth in 16 weeks. It’s not an illusion of growth. It’s your own eyelashes — only better.

How LATISSE® works.
LATISSE® makes lash growth possible because of its active ingredient:
bimatoprost. Although the precise mechanism of action is unknown, LATISSE® is believed to affect the growth (anagen) phase of the eyelash hair cycle in two ways: first, it increases the length of this phase, and second, it increases the number of hairs in this growth phase.

The history behind LATISSE®.
Although LATISSE® is a treatment for inadequate or not enough eyelashes, it was developed through years of research by Allergan, a pharmaceutical leader with expertise in eye care products.

Important Safety Information

Contraindications: LATISSE® is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.

Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) 0.03% or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.

Increased iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution (LUMIGAN®) was instilled directly onto the eye. Although iridal pigmentation was not reported in clinical studies with LATISSE®, patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent.

Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes.

There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces.

LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated.

LATISSE® contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.

Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.

Dosage and Administration: Apply nightly directly to the skin of the upper eyelid margin at the base of the eyelashes using the accompanying applicators. Blot any excess solution beyond the eyelid margin. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator. Do not apply to the lower eyelash line.

Click here for full prescribing information.

<back

If you have any questions or would like more information, please contact us at 828-268-0082, email us, or use our online request form.